Compare LBTYK & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBTYK | INSP |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | Bermuda | United States |
| Employees | 6820 | N/A |
| Industry | Cable & Other Pay Television Services | Medical/Dental Instruments |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.8B |
| IPO Year | N/A | 2018 |
| Metric | LBTYK | INSP |
|---|---|---|
| Price | $11.23 | $138.09 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $127.07 |
| AVG Volume (30 Days) | 879.0K | ★ 1.5M |
| Earning Date | 01-01-0001 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.77 |
| EPS | N/A | ★ 1.48 |
| Revenue | ★ $4,770,600,000.00 | $882,622,000.00 |
| Revenue This Year | $13.22 | $14.97 |
| Revenue Next Year | $1.67 | $11.81 |
| P/E Ratio | ★ N/A | $92.68 |
| Revenue Growth | ★ 170.50 | 16.81 |
| 52 Week Low | $9.21 | $70.77 |
| 52 Week High | $14.48 | $216.01 |
| Indicator | LBTYK | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 52.96 | 76.95 |
| Support Level | $10.88 | $132.39 |
| Resistance Level | $11.49 | $142.56 |
| Average True Range (ATR) | 0.30 | 7.26 |
| MACD | 0.02 | 3.75 |
| Stochastic Oscillator | 62.37 | 90.18 |
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.